Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yihai Kerry Arawana Holdings Co Ltd
SZSE:300999
|
CN |
Pieris Pharmaceuticals Inc
Depreciation & Amortization
Pieris Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Pieris Pharmaceuticals Inc
Glance View
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. The company is headquartered in Boston, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2014-12-18. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.
